Publications - IR Sant Pau

Search

01/10/2025 Assessing outcomes emerging after conversion to regular approval for cancer drug indications granted accelerated approval, 1992-2021

Tibau, A, Romano, A, Liu, ITT, Han, J, Cliff, ERS, Kesselheim, AS. Assessing outcomes emerging after conversion to regular approval for cancer drug indications granted accelerated approval, 1992-2021. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2025; 117(10)DOI:10.1093/jnci/djaf195. PMID:40690366. IF:7.200(Q1/2D).

01/10/2025 Exploring communication preferences for disclosing breast cancer risk in women with a family history

López-Fernández, A, Pardo, M, Pérez-Ballestero, E, Darder, E, Alfonso, R, Torres-Esquius, S, Garcés, VN, Cajal, TRY, Brunet, J, Balmaña, J. Exploring communication preferences for disclosing breast cancer risk in women with a family history. Journal of Genetic Counseling. 2025; 34(5)DOI:10.1002/jgc4.70114. PMID:40965181. IF:1.900(Q2/5D).

30/09/2025 Multidisciplinary approach for patients with early and locally advanced non-small cell lung cancer (NSCLC): 2nd Spanish Lung Cancer Group (GECP) expert consensus statement

Ospina-Serrano, AV, González-Larriba, JL, Nadal, E, Trancho, FH, Bosch-Barrera, J, Calvo, V, Bolufer-Nadal, S, de la Cruz, JLCC, Macía-Vidueira, I, Alvarez-Kindelán, A, Del Barco-Morillo, E, Bernabé-Caro, R, Casal-Rubio, J, Cilleruelo-Ramos, A, Cobo-Dols, M, Dómine-Gómez, M, Figueroa-Almánzar, S, Insa-Mollá, A, Jarabo-Sarceda, JR, Jiménez-Maestre, U, López-Castro, R, Majem, M, Martinez-Marti, A, Téllez, EM, Sánchez-Lorente, D, López-Valcárcel, M, Couñago, F, Garcia-Campelo, R, de Castro, J, Massuti-Sureda, B, Provencio, M. Multidisciplinary approach for patients with early and locally advanced non-small cell lung cancer (NSCLC): 2nd Spanish Lung Cancer Group (GECP) expert consensus statement. Translational Lung Cancer Research. 2025; 14(9)DOI:10.21037/tlcr-2025-619. PMID:41132973. IF:3.500(Q1/3D).

22/09/2025 A network meta-analysis of the safety of systemic treatments in patients with metastatic hormone-sensitive prostate cancer

Di Maio, M, Gonzalez-Billalabeitia, E, Marandino, L, Maroto, P, Timsit, MO, Luccarini, I, Robinson, P, Van Sanden, S, Hadaschik, BA. A network meta-analysis of the safety of systemic treatments in patients with metastatic hormone-sensitive prostate cancer. Frontiers in Oncology. 2025; 15DOI:10.3389/fonc.2025.1468928. PMID:41059299. IF:3.300(Q2/4D).

01/09/2025 Trends in time to withdrawal and full approval of accelerated approval cancer drug indications (1992-2024)

Jenei, K, Hahn, G, Kesselheim, AS, Tibau, A. Trends in time to withdrawal and full approval of accelerated approval cancer drug indications (1992-2024). Journal Of Cancer Policy. 2025; 45DOI:10.1016/j.jcpo.2025.100597. PMID:40472969. IF:(Q/D).

01/09/2025 Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial

Remon, J, Bironzo, P, Girard, N, Bigay-Game, L, Juan-Vidal, O, de Castro, J, Reguart, N, Greillier, L, Cousin, S, Dansin, E, Majem, M, Bernabe, R, Martinez, JM, Diaz, M, Meya, A, Alcalá-López, D, Garcia-Sanz, A, Righi, L, Novello, S, Besse, B. Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial. LANCET ONCOLOGY. 2025; 26(9)DOI:10.1016/S1470-2045(25)00300-6. PMID:40907517. IF:35.900(Q1/1D).

01/09/2025 Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial

Tombal, B, Choudhury, A, Saad, F, Gallardo, E, Soares, A, Loriot, Y, Mcdermott, R, Rodriguez-Vida, A, Velho, PI, Nolè, F, Cruz, F, Roumeguere, T, Daugaard, G, Yamamura, R, Bompas, E, Maroto, P, Veiga, FG, Skoneczna, I, Trindade, KMD, Carcano, FM, Lecouvet, F, Coens, C, Poncet, C, Fournier, B, Gillessen, S, Crua, F. Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial. ANNALS OF ONCOLOGY. 2025; 36(9)DOI:10.1016/j.annonc.2025.05.011. PMID:40450503. IF:65.400(Q1/1D).

14/08/2025 A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors

de Bono, JS, Williams, A, Melero, I, Jayaram, A, Hawley, JE, de Speville, BD, Moreno, I, Castellano, D, Reig, O, Knapen, DG, Anguera, G, Martinez, J, Gort, E, de Jonge, M, Alonso-Romero, JL, Boni, V, Perez-Gracia, JL, Falcon, A, de Groot, DJ, Pierce, AJ, Leishman, AJ, Lloyd, P, Bartlett, PD, Bland-Ward, P, Chau, A, Song, MJ, Duffy, K, Hashimoto, K, de Vries, E. A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors. CLINICAL CANCER RESEARCH. 2025; 31(16)DOI:10.1158/1078-0432.CCR-24-3581. PMID:40094417. IF:10.200(Q1/1D).

01/08/2025 A randomized study of 2 risk assessment models for individualized breast cancer risk estimation

López-Fernández, A, Duran-Lozano, L, Villacampa, G, Pardo, M, Pérez, E, Darder, E, Vallmajó, A, Alfonso, R, Cruellas, M, Roqué, A, Cartró, M, Bareas, A, Carrasco, E, Rezqallah, A, Jimenez-Macedo, AR, Torres-Esquius, S, Torres, M, Lopez, C, Espinosa, M, Teulé, A, Munté, E, Tuset, N, Diez, O, Feliubadaló, L, Lázaro, C, Llort, G, Carver, T, Ficorella, L, Mavaddat, N, Mercadé, A, Antoniou, AC, Brunet, J, Cajal, TRY, Balmaña, J. A randomized study of 2 risk assessment models for individualized breast cancer risk estimation. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2025; 117(8)DOI:10.1093/jnci/djaf067. PMID:40170233. IF:7.200(Q1/2D).

01/08/2025 Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma

van der Heijden, MS, Powles, T, Gupta, S, Loriot, Y, Galsky, MD, Valderrama, BP, Sridhar, SS, Yu, EY, Iyer, G, Kikuchi, E, Castellano, D, Hoffman-Censits, J, Drakaki, A, Mar, N, Rey, JPM, Vulsteke, C, Arafat, W, Duran, I, Dawson, NA, Swami, U, Gorla, S, Moreno, BH, Yu, X, Lu, YT, Bedke, J. Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma. ESMO Open. 2025; 10(8)DOI:10.1016/j.esmoop.2025.105544. PMID:40795788. IF:8.300(Q1/2D).

25/07/2025 Triplet systemic therapy for hormone-sensitive prostate cancer: a critical review with a multidisciplinary approach

Zapatero, A, Alonso-Gordoa, T, Antolín, AR, Couñago, F, Sanmamed, N, Esteban, MD, Valcárcel, ML, Manneh, R, Borque-Fernando, A, González, NS, Maroto, P. Triplet systemic therapy for hormone-sensitive prostate cancer: a critical review with a multidisciplinary approach. Oncology Reviews. 2025; 19DOI:10.3389/or.2025.1599292. PMID:40787089. IF:(Q/D).

15/07/2025 Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non-Small Cell Lung Cancer Update From the COAST Randomized Clinical Trial

Aggarwal, C, Martinez-Marti, A, Majem, M, Barlesi, F, Carcereny, E, Chu, Q, Monnet, I, Sánchez-Hernández, A, Dakhil, S, Camidge, DR, Pillet, M, Brown, M, Paliompeis, C, Dowson, A, Cooper, ZA, Kumar, R, Herbst, RS. Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non-Small Cell Lung Cancer Update From the COAST Randomized Clinical Trial. JAMA Network Open. 2025; 8(7)DOI:10.1001/jamanetworkopen.2025.18440. PMID:40663352. IF:9.700(Q1/1D).

01/07/2025 Prediction of 90-day mortality among cancer patients with unplanned hospitalisation: a retrospective validation study of three prognostic scores

Uyar, GC, Mirallas, O, Baskurt, K, Martin-Cullell, B, Yesilbas, E, Recuero-Borau, J, Kaya, S, Garcés, VN, Yücel, SE, Cano, KSV, Gómez-Puerto, D, Gómez, AP, de Torres, CS, Öksüzoglu, ÖBÇ, Serradell, S, Dienstmann, R, Sutcuoglu, O. Prediction of 90-day mortality among cancer patients with unplanned hospitalisation: a retrospective validation study of three prognostic scores. Lancet Regional Health-Europe. 2025; 54DOI:10.1016/j.lanepe.2025.101317. PMID:40672056. IF:13.000(Q1/1D).

01/07/2025 Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC (vol 6, 100815, 2025)

Cappuzzo, F, Zvirbule, Z, Korbenfeld, E, Kolb-Sielecki, J, Isla, D, Szczesna, A, Sanchez, AYC, Bustillos, A, Liu, XY, Young, F, Tosti, N, Monteiro, MF, Majem, M. Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC (vol 6, 100815, 2025). Jto Clinical And Research Reports. 2025; 6(7)DOI:10.1016/j.jtocrr.2025.100842. PMID:40534993. IF:(Q/D).

01/07/2025 Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer

Pietrantonio, F, Salvatore, L, Esaki, T, Modest, DP, Lopez-Bravo, DP, Taieb, J, Karamouzis, MV, Ruiz-Garcia, E, Kim, TW, Kuboki, Y, Meriggi, F, Cunningham, D, Yeh, KH, Chan, EMY, Chao, JS, Tran, Q, Cremolini, C, Fakih, M. Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(19)DOI:10.1200/JCO-24-02026. PMID:40215429. IF:41.900(Q1/1D).

01/07/2025 Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial

Bergmann, L, Albiges, L, Ahrens, M, Gross-Goupil, M, Boleti, E, Gravis, G, Flechon, A, Grimm, MO, Bedke, J, Barthélémy, P, Castellano, D, Mellado, B, Ivanyi, P, Rottey, S, Flörcken, A, Suarez, C, Maroto, P, Grünwald, V, Oosting, SF, Kopecky, J, Zschäbitz, S, Boegemann, M, Buchler, T, Niegisch, G, Goebell, PJ, Waddell, T, Joly, F, Priou, F, Retz, M, Siemer, S, Zimmermann, U, Deckbar, D, Burkholder, I, Hartmann, A, Haanen, JB. Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial. ANNALS OF ONCOLOGY. 2025; 36(7)DOI:10.1016/j.annonc.2025.03.016. PMID:40180121. IF:65.400(Q1/1D).

01/07/2025 Relevance of ABCG2 and SRPK1 genetic variants in irinotecan-induced severe toxicity

Da Silva, IM, Riera, P, Bernal, S, Manrique, ACV, Cullell, BM, Paez, D. Relevance of ABCG2 and SRPK1 genetic variants in irinotecan-induced severe toxicity. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.05.046. PMID:. IF:65.400(Q1/1D).

01/07/2025 A retrospective single-center analysis of treatment strategies and real-world outcomes in locally advanced pancreatic cancer

Beltran, JS, Serda, PC, Cardozo, AR, Pérez, MAM, Manrique, ACV, Paez, D, Cullell, BM. A retrospective single-center analysis of treatment strategies and real-world outcomes in locally advanced pancreatic cancer. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.05.288. PMID:. IF:65.400(Q1/1D).

01/07/2025 Prognostic significance of the systemic inflammation response index (SIRI) and nutritional status in metastatic pancreatic cancer: Results from the PANTHEIA-SEOM study

Ponce, CG, Méndez, AM, Plazas, JG, Benavente, MDL, Serda, PC, Vazquez, EB, Conesa, MADLAV, Gil, RHS, Gomez, VL, Alfonso, AL, Custodio-Cabello, S, Paladines, WGP, Carmena, MD, Mercade, TM, Tabares, MLS, Martínez, IP, Gutierrez, LC, Martin, AJM, Fonseca, PJ, Pacheco-Barcia, VE. Prognostic significance of the systemic inflammation response index (SIRI) and nutritional status in metastatic pancreatic cancer: Results from the PANTHEIA-SEOM study. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.05.304. PMID:. IF:65.400(Q1/1D).

01/07/2025 Impact of the systemic inflammation index (SIRI) and artificial intelligence(AI)-based muscle mass (FocusedON® software) on chemotherapy toxicity and prognosis in metastatic pancreatic cancer: A proof-of-concept from the PANTHEIA-Spanish Society of Medical Oncology (SEOM) study group

Pacheco-Barcia, VE, Méndez, AM, Plazas, JG, Rus, ND, Benavente, MDL, Cullell, BM, Gomez, VL, Vazquez, EB, Conesa, MADLAV, Fernandez, SP, Alfonso, AL, Castet, F, Adeva, JA, Fabregat, C, Abad, DG, Contreras, PZ, Carmona-Bayonas, A, Fonseca, PJ, Gutierrez, LC, Martin, AJM. Impact of the systemic inflammation index (SIRI) and artificial intelligence(AI)-based muscle mass (FocusedON® software) on chemotherapy toxicity and prognosis in metastatic pancreatic cancer: A proof-of-concept from the PANTHEIA-Spanish Society of Medical Oncology (SEOM) study group. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.05.305. PMID:. IF:65.400(Q1/1D).

14/06/2025 Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial

Paz-Ares, L, Borghaei, H, Liu, S, Peters, S, Herbst, RS, Stencel, K, Majem, M, Sendur, MAN, Czyzewicz, G, Caro, RB, Lee, KH, Johnson, ML, Karadurmus, N, Grohé, C, Baka, S, Csoszi, T, Ahn, JS, Califano, R, Yang, TY, Kemal, Y, Ballinger, M, Cuchelkar, V, Graupner, V, Lin, YC, Chakrabarti, D, Bhatt, K, Cai, G, Iannone, R, Reck, M. Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial. LANCET. 2025; 405(10495)DOI:10.1016/S0140-6736(25)01011-6. PMID:40473449. IF:88.500(Q1/1D).

01/06/2025 Induction of neoantigen-specific immune responses by VB10.NEO in combination with atezolizumab in heavily pretreated patients with advanced solid tumors: Final analysis of the phase 1b VB N-02 trial.

Ochsenreither, S, Anguera, G, Dieter, S, Trikalinos, N, Fu, SQ, Fernández, BC, Ferrandiz, AC, Kim, SY, Rodriguez, LM, Berg, KCG, Hassan, HIB, Rosholm, A, Fredriksen, AB. Induction of neoantigen-specific immune responses by VB10.NEO in combination with atezolizumab in heavily pretreated patients with advanced solid tumors: Final analysis of the phase 1b VB N-02 trial.. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(16_SUPPL)DOI:10.1200/JCO.2025.43.16_suppl.2639. PMID:. IF:41.900(Q1/1D).

01/06/2025 Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer

Herbst, RS, John, T, Grohé, C, Goldman, JW, Kato, T, Laktionov, K, Bonanno, L, Tiseo, M, Majem, M, Dómine, M, Ahn, MJ, Kowalski, DM, Pérol, M, Sriuranpong, V, Özgüroglu, M, Bhetariya, P, Markovets, A, Rukazenkov, Y, Muldoon, C, Robichaux, J, Hartmaier, R, Tsuboi, M, Wu, YL. Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer. NATURE MEDICINE. 2025; 31(6)DOI:10.1038/s41591-025-03577-y. PMID:40097663. IF:50.000(Q1/1D).

01/06/2025 Predictors of withdrawal of anticancer drug indications granted accelerated approval: a retrospective cohort study

Tibau, A, Cliff, ERS, Romano, A, Borrell, M, Molto, C, Kesselheim, AS. Predictors of withdrawal of anticancer drug indications granted accelerated approval: a retrospective cohort study. Eclinicalmedicine. 2025; 84DOI:10.1016/j.eclinm.2025.103088. PMID:40687736. IF:10.000(Q1/1D).

13/05/2025 Pilot Investigation on Markers of Bone Metabolism, Angiogenesis, and Neuroendocrine Activity as Potential Predictors of Survival of Metastatic Prostate Cancer Patients with Bone Metastases

Ortiz, MA, Anguera, G, Cantó, E, Alejandre, J, Mora, J, Osuna-Gómez, R, Mulet, M, Mora, P, Antonijuan, A, Sánchez, S, Ramírez, O, Orantes, V, Maroto, P, Vidal, S. Pilot Investigation on Markers of Bone Metabolism, Angiogenesis, and Neuroendocrine Activity as Potential Predictors of Survival of Metastatic Prostate Cancer Patients with Bone Metastases. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025; 26(10)DOI:10.3390/ijms26104669. PMID:40429810. IF:4.900(Q1/3D).

01/05/2025 Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC

Cappuzzo, F, Zvirbule, Z, Korbenfeld, E, Kolb-Sielecki, J, Isla, D, Szczesna, A, Sanchez, AYC, Bustillos, A, Liu, XY, Young, F, Tosti, N, Monteiro, MF, Majem, M. Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC. Jto Clinical And Research Reports. 2025; 6(5)DOI:10.1016/j.jtocrr.2025.100815. PMID:40248457. IF:(Q/D).

18/04/2025 The Effect of Staging Intervals on Progression-Free Survival in Registration Studies of Oncologic Drugs: A Meta-Analysis

Zuellig, JA, Adam, R, Udry, F, Tibau, A, Seruga, B, Ocana, A, Amir, E, Templeton, AJ. The Effect of Staging Intervals on Progression-Free Survival in Registration Studies of Oncologic Drugs: A Meta-Analysis. Cancers. 2025; 17(8)DOI:10.3390/cancers17081359. PMID:40282533. IF:4.400(Q2/3D).

01/04/2025 Will I feel better? Raising the bar for quality of life in oncology

Tibau, A, Romano, A, Kesselheim, AS. Will I feel better? Raising the bar for quality of life in oncology. Nature Reviews Clinical Oncology. 2025; 22(4)DOI:10.1038/s41571-025-01002-4. PMID:40021787. IF:82.200(Q1/1D).

01/04/2025 Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study

Del Muro, XG, López-Bravo, DP, Cuéllar-Rivas, MA, Maroto, P, Giannatempo, P, Castellano, D, Climent, MA, Valderrama, BP, de Liaño, AG, López-Montero, L, Mina, L, Alcalá-López, D, Sampayo-Cordero, M, Necchi, A. Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study. European Urology Oncology. 2025; 8(2)DOI:10.1016/j.euo.2024.04.021. PMID:38749903. IF:9.300(Q1/1D).

01/04/2025 A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial

Soo, RA, Vervita, K, Früh, M, Cho, B, Majem, M, Abreu, DR, Ribi, K, Callejo, A, Moran, T, Gomez, MD, Provencio, M, Addeo, A, Han, JY, Granados, ALO, Reck, M, Blasco, A, Campelo, RG, González, MAS, Britschgi, C, Roschitzki-Voser, H, Ruepp, B, Gasca-Ruchti, A, Haberecker, M, Dafni, U, Peters, S, Stahel, RA. A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial. LUNG CANCER. 2025; 202DOI:10.1016/j.lungcan.2025.108454. PMID:40023017. IF:4.400(Q1/2D).

28/03/2025 Beyond the status quo: when disease volume and metastatic timing are not enough to personalize treatment in mHSPC

Borque-Fernando, A, Alonso-Gordoa, T, Juan-Fita, MJ, Campos, FL, Pérez-Fentes, DA, Vilaseca, A, Agut, CM, Usán, P, Rey, PM. Beyond the status quo: when disease volume and metastatic timing are not enough to personalize treatment in mHSPC. Future Oncology. 2025; 21(8)DOI:10.1080/14796694.2025.2468569. PMID:40029138. IF:2.600(Q3/6D).

01/03/2025 Baseline PD-L1 expression in circulating neutrophils predicts immune-related adverse events (irAEs) in patients with extensive-stage small-cell lung cancer from CANTABRICO trial

Piedra, A, Guinart-Cuadra, A, Recio, SM, Mulet, M, Atenza, CZ, Alejandre, J, Beltran, JS, Joaquín, AB, Sullivan, IG, López, JS, Casado, MDI, Aperribay, EA, Paz-Ares, L, Tain, PD, Vega, ALM, Callejo, A, Martos, JLL, Dominguez, M, Vidal, S, Majem, M. Baseline PD-L1 expression in circulating neutrophils predicts immune-related adverse events (irAEs) in patients with extensive-stage small-cell lung cancer from CANTABRICO trial. Journal of Thoracic Oncology. 2025; 20(3)DOI:. PMID:. IF:20.800(Q1/1D).

01/03/2025 TACTI-004: A double-blinded, randomized phase III trial in patients with advanced/metastatic non-small cell lung cancer receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (P) and chemotherapy (C) versus placebo plus P plus C

Majem, M, O'Byrne, KJ, Lo Russo, G, Mueller, C, Triebel, F. TACTI-004: A double-blinded, randomized phase III trial in patients with advanced/metastatic non-small cell lung cancer receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (P) and chemotherapy (C) versus placebo plus P plus C. Journal of Thoracic Oncology. 2025; 20(3)DOI:. PMID:. IF:20.800(Q1/1D).

01/03/2025 Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis

Gillessen, S, Tombal, B, Turco, F, Choudhury, A, Rodriguez-Vida, A, Gallardo, E, Velho, PI, Nolè, F, Cruz, F, Loriot, Y, McDermott, R, Roumeguere, T, Daugaard, G, Yamamura, R, Bompas, E, Maroto, P, Polo, MH, da Trindade, KM, Preto, DD, Skoneczna, I, Lecouvet, F, Coens, C, Fournier, B, Saad, F. Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis. EUROPEAN UROLOGY. 2025; 87(3)DOI:10.1016/j.eururo.2024.11.027. PMID:39827019. IF:25.200(Q1/1D).

01/03/2025 Patient-reported outcomes from CANTABRICO: Durvalumab plus platinum-etoposide in first-line treatment of extensive stage small cell lung cancer

Casado, MDI, Aperribay, EA, Campelo, MRG, Blanco, MCM, Tain, PD, Piqueras, MMLB, Vega, ALM, Mateos, LAL, Rodriguez, JMO, Calderon, VG, Majem, M, Hernandez, AS, de la Rosa, CA, Cabellos, RA, Sureda, BM, Baret, M, Martos, JLL, Dominguez, M, Paz-Ares, L. Patient-reported outcomes from CANTABRICO: Durvalumab plus platinum-etoposide in first-line treatment of extensive stage small cell lung cancer. Journal of Thoracic Oncology. 2025; 20(3)DOI:. PMID:. IF:20.800(Q1/1D).

01/03/2025 First-line (1L) fulzerasib plus cetuximab in KRAS G12Cm advanced NSCLC: Updated efficacy and safety from KROCUS study

Majem, M, Gregorc, V, Lo Russo, G, Maio, M, Salvagni, S, Calderon, VG, Cao, MG, Contreras, SS, Koumarianou, A, Bearz, A, Caro, RB, Viteri, S, Sanmamed, MF, Zagouri, F, Bueno, MTM, Zhang, Y, Shan, Y, Zhu, H, Rosell, R. First-line (1L) fulzerasib plus cetuximab in KRAS G12Cm advanced NSCLC: Updated efficacy and safety from KROCUS study. Journal of Thoracic Oncology. 2025; 20(3)DOI:. PMID:. IF:20.800(Q1/1D).

01/03/2025 Long-term survivors with extensive-stage small-cell lung cancer treated with first-line durvalumab plus carboplatin and etoposide: The CANTABRICO trial

Casado, MDI, Aperribay, EA, Campelo, MRG, Blanco, CM, Tain, PD, Piqueras, MMLB, Vega, ALM, Mateos, LAL, Rodriguez, JMO, Calderon, VG, Majem, M, Hernandez, AS, de la Rosa, CA, Cabellos, RA, Sureda, BM, Baret, M, Martos, JLL, Dominguez, M, Paz-Ares, L. Long-term survivors with extensive-stage small-cell lung cancer treated with first-line durvalumab plus carboplatin and etoposide: The CANTABRICO trial. Journal of Thoracic Oncology. 2025; 20(3)DOI:. PMID:. IF:20.800(Q1/1D).

01/03/2025 Analysis of tumor budding as a prognostic factor for recurrence in patients with stage II and III colon cancer. Experience in a tertiary hospital

Rueda-Lara, A, Viñal, D, Martínez-Pérez, D, Alameda-Guijarro, M, Martin-Montalvo, G, Martínez-Recio, S, Peña-Lopez, J, Jiménez-Bou, D, Ruíz-Gutiérrez, I, García-Leal, A, Zwisler-Contreras, P, Ghanem, I, Custodio, AB, Pérez-Wert, P, Gutiérrez-Sainz, L, Palacios, ME, Feliu, J, Rodríguez-Salas, N. Analysis of tumor budding as a prognostic factor for recurrence in patients with stage II and III colon cancer. Experience in a tertiary hospital. ONCOLOGIST. 2025; 30(3)DOI:10.1093/oncolo/oyaf027. PMID:40152315. IF:4.200(Q2/3D).

10/02/2025 Impact of site of metastatic involvement on IMDC classification in metastatic renal cell carcinoma patients treated with immunotherapy.

Fernandez-Mañas, L, Ortiz, I, Pozas, J, Beland, C, Larkin, J, Moll-Febrer, A, González-Aguado, L, Beltran, JS, Anguera, G, Navarro, N, Rodriguez-Vida, A, Novella, SR, Sierra, M, Carrasco, A, González, NS, Yonamine, EPM, Maeso, IG, Figols, M, Alcalá, MM, Reig, O. Impact of site of metastatic involvement on IMDC classification in metastatic renal cell carcinoma patients treated with immunotherapy.. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(5_SUPPL)DOI:10.1200/JCO.2025.43.5_suppl.483. PMID:. IF:41.900(Q1/1D).

10/02/2025 Impact of deferred cytoreductive nephrectomy in the era of the immunotherapy in metastatic renal cell carcinoma: A multicenter retrospective study.

Rioja, P, Passarella, C, Angel, M, Valderrama, W, Bosma, F, Anguera, G, Gomez, V, Ruiz-Granados, A, Plata, D, Laguado, MIZ, Orta-Ruiz, A, Gandur-Quiroga, MN, Bourlon, MT, Grande, E, Manneh, R, Molina-Cerrillo, J, Maroto-Rey, P, Sade, JP, Castellano, D. Impact of deferred cytoreductive nephrectomy in the era of the immunotherapy in metastatic renal cell carcinoma: A multicenter retrospective study.. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(5_SUPPL)DOI:10.1200/JCO.2025.43.5_suppl.502. PMID:. IF:41.900(Q1/1D).

10/02/2025 Effectiveness and safety of first-line atezolizumab in locally advanced or metastatic urothelial cancer: The IMFLAME study.

Lista, AGD, Romero-Laorden, N, Gajate, P, Orta-Ruiz, A, Jiménez, JGD, Miranda, MJ, Estévez, SV, Molins, C, Pernaut, C, Cordero, MG, Fernández, O, Sánchez, JG, Maeso, IG, Blazquez, PR, Reig, O, Maroto-Rey, P, Martín, A, Ramirez, I, Puente, J. Effectiveness and safety of first-line atezolizumab in locally advanced or metastatic urothelial cancer: The IMFLAME study.. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(5_SUPPL)DOI:10.1200/JCO.2025.43.5_suppl.720. PMID:. IF:41.900(Q1/1D).

04/02/2025 Determinants of 5-year survival in patients with advanced NSCLC with PD-L1=50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry

Cortellini, A, Brunetti, L, Di Fazio, GR, Garbo, E, Pinato, DJ, Naidoo, J, Katz, A, Loza, M, Neal, JW, Genova, C, Gettinger, S, Kim, SY, Jayakrishnan, R, El Zarif, T, Russano, M, Pecci, F, Di Federico, A, Awad, M, Alessi, J, Montrone, M, Owen, DH, Signorelli, D, Fidler, MJ, Li, MJ, Camerini, A, De Giglio, A, Young, L, Vincenzi, B, Metro, G, Passiglia, F, Yendamuri, S, Guida, A, Ghidini, M, Awosika, NO, Napolitano, A, Fulgenzi, CAM, Grisanti, S, Grossi, F, D'Incecco, A, Josephides, E, Van Hemelrijck, M, Russo, A, Gelibter, A, Spinelli, G, Verrico, M, Tomasik, B, Giusti, R, Newsom-Davis, T, Bria, E, Sebastian, M, Rost, M, Forster, M, Mukherjee, U, Landi, L, Mazzoni, F, Aujayeb, A, Dupont, M, Curioni-Fontecedro, A, Chiari, R, Pantano, F, Morabito, A, Leonetti, A, Friedlaender, A, Addeo, A, Zoratto, F, De Tursi, M, Cantini, L, Roca, E, Mountzios, G, Della Gravara, L, Kalvapudi, S, Inno, A, Bironzo, P, Barros, RD, O'Reilly, D, Bell, J, Karapanagiotou, E, Monnet, I, Baena, J, Macerelli, M, Majem, M, Agustoni, F, Cortinovis, DL, Tonini, G, Minuti, G, Bennati, C, Mezquita, L, Gorría, T, Servetto, A, Beninato, T, Lo Russo, G, Rogado, J, Moliner, L, Biello, F, Nana, FA, Dingemans, AM, Aerts, JGJ, Ferrara, R, Torri, V, Abu Hejleh, T, Takada, K, Naqash, AR, Garassino, M, Peters, S, Wakelee, H, Nassar, AH, Ricciuti, B. Determinants of 5-year survival in patients with advanced NSCLC with PD-L1=50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. Journal for ImmunoTherapy of Cancer. 2025; 13(2)DOI:10.1136/jitc-2024-010674. PMID:39904562. IF:10.600(Q1/1D).

01/02/2025 A cross-sectional analysis from a real-world cohort of patients with microsatellite instability colorectal cancer (MSI-CRC) with metastatic disease from the Spanish RETUD registry.

Castro, CG, López, S, Garcia-Alfonso, P, Martinez, CF, González, BD, Ortiz, MJ, Paez, D, Lopez, CM, La Casta, A, Sosa, MM, Valera, JS, Ghanem, I, Vidal-Tocino, R, Santos, C, Garcia-Benito, C, Jimenez, E, Guillot, M, Verdaguer, H, Montes, AFF. A cross-sectional analysis from a real-world cohort of patients with microsatellite instability colorectal cancer (MSI-CRC) with metastatic disease from the Spanish RETUD registry.. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(4_SUPPL)DOI:10.1200/JCO.2025.43.4_suppl.178. PMID:. IF:41.900(Q1/1D).

01/02/2025 Plasma shallow whole-genome sequencing profiling in patients with RASWT metastatic colorectal cancer (mCRC) undergoing first-line anti-EGFR therapy.

Martelli, V, Barrull, JV, Fernandez-Rodríguez, C, Gibert, J, Moreno, A, Louhamane, A, Linares-Aceituno, J, Garcia-Alfonso, P, Paez, D, Alonso, V, Espana, MAG, Santos, C, Duran, G, Elez, E, Paricio, BB, Tabernero, J, Salazar, R, Aranda, E, Toledo, RA, Montagut, CO. Plasma shallow whole-genome sequencing profiling in patients with RASWT metastatic colorectal cancer (mCRC) undergoing first-line anti-EGFR therapy.. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(4_SUPPL)DOI:10.1200/JCO.2025.43.4_suppl.214. PMID:. IF:41.900(Q1/1D).

01/02/2025 A cross-sectional analysis from a real-world cohort of patients with microsatellite instability colorectal cancer (MSI-CRC) with localized disease from the Spanish RETUD registry.

Montes, AFF, Lopez, CM, Lopez, S, Martinez, CF, Paez, D, Gonzalez, BD, Espana, MAG, Garcia-Benito, C, Vidal-Tocino, R, Sosa, MM, Valera, JS, Garcia-Alfonso, P, Ghanem, I, La Casta, A, Gallego, J, Verdaguer, H, Santos, C, Jimenez, E, Gravalos, C. A cross-sectional analysis from a real-world cohort of patients with microsatellite instability colorectal cancer (MSI-CRC) with localized disease from the Spanish RETUD registry.. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(4_SUPPL)DOI:10.1200/JCO.2025.43.4_suppl.173. PMID:. IF:41.900(Q1/1D).

01/02/2025 Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research Recommendations in Women with Breast Cancer

Olmos, VP, Pollán, M, de Larrea-Baz, NF, Fernández-Morata, J, Ruiz-Moreno, E, García-Pérez, J, Castelló, A, Sierra, MA, Lucas, P, Alonso-Ledesma, I, Stradella, A, Cantos, B, Cajal, TRY, Santisteban, M, Seguí, MA, Bertrán, AS, Granja, M, Camps-Herrero, J, Recalde, S, Mendez, M, Verges, NC, Pérez-Gómez, B, Pastor-Barriuso, R, Lope, V. Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research Recommendations in Women with Breast Cancer. Cancers. 2025; 17(4)DOI:10.3390/cancers17040708. PMID:40002301. IF:4.400(Q2/3D).

27/01/2025 Therapeutic alliance in a stepped digital psychosocial intervention for breast cancer patients: findings from a multicentre randomised controlled trial

Flix-Valle, A, Medina, JC, Souto-Sampera, A, Arizu-Onassis, A, Juan-Linares, E, Serra-Blasco, M, Ciria-Suárez, L, Feixas, G, Ochoa-Arnedo, C. Therapeutic alliance in a stepped digital psychosocial intervention for breast cancer patients: findings from a multicentre randomised controlled trial. BJPsych Open. 2025; 11(1)DOI:10.1192/bjo.2024.844. PMID:39865983. IF:3.500(Q1/3D).

20/01/2025 Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS)

Martin-Broto, J, Diaz-Beveridge, R, Moura, D, Ramos, R, Martinez-Trufero, J, Carrasco, I, Sebio, A, Gonzalez-Billalabeitia, E, Gutierrez, A, Fernandez-Jara, J, Hernandez-Vargas, L, Cruz, J, Valverde, C, Hindi, N. Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS). JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(3)DOI:10.1200/JCO.24.00358. PMID:39356980. IF:41.900(Q1/1D).

01/01/2025 Adjuvant Immunotherapy After Resected Melanoma: Survival Outcomes, Prognostic Factors and Patterns of Relapse

Martinez-Recio, S, Molina-Pérez, MA, Muñoz-Couselo, E, Sevillano-Tripero, AR, Aya, F, Arance, A, Orrillo, M, Martin-Liberal, J, Fernandez-Morales, L, Lesta, R, Quindós-Varela, M, Nieva, M, Vidal, J, Martinez-Perez, D, Barba, A, Majem, M. Adjuvant Immunotherapy After Resected Melanoma: Survival Outcomes, Prognostic Factors and Patterns of Relapse. Cancers. 2025; 17(1)DOI:10.3390/cancers17010143. PMID:39796770. IF:4.400(Q2/3D).

01/01/2025 Quality of Life and Patient-Reported Outcomes in Patients With Osteosarcoma: A Systematic Review

Sebio, A, Berger, C, Tabone, MD, Fernandez, N, Tardy, F, Grootenhuis, M, Palmerini, E, Gaspar, N, van de Sande, M, Haveman, LM. Quality of Life and Patient-Reported Outcomes in Patients With Osteosarcoma: A Systematic Review. EUROPEAN JOURNAL OF CANCER CARE. 2025; 2025(1)DOI:10.1155/ecc/5802523. PMID:. IF:1.900(Q2/4D).

17/12/2024 First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study

Piedra, A, Martínez-Recio, S, Hernández, A, Morán, T, Arriola, E, Recuero-Borau, J, Cobo, M, Cordeiro, P, Mosquera, J, Fernández, M, García-Campelo, R, Calles, A, Alvarez, R, Zapata-García, M, Isla, D, Callejo, A, Iranzo, P, Serra-López, J, Barba, A, Sullivan, I, Felip, E, Majem, M. First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study. Frontiers in Oncology. 2024; 14DOI:10.3389/fonc.2024.1510278. PMID:39741981. IF:3.300(Q2/4D).

01/11/2024 SEOM clinical guidelines for cancer anorexia-cachexia syndrome (2023).

Soria Rivas A, Escobar Álvarez Y, Blasco Cordellat A, Majem Tarruella M, Molina Mata K, Motilla de la Cámara M, Del Mar Muñoz Sánchez M, Zafra Poves M, Beato Zambrano C, Cabezón Gutierrez L. SEOM clinical guidelines for cancer anorexia-cachexia syndrome (2023).. Clinical & Translational Oncology. 2024; 26(11)DOI:10.1007/s12094-024-03502-8. PMID:38822976. IF:(Q/D).

01/06/2022 The spectrum of building block conformers sustains the biophysical properties of clinically-oriented self-assembling protein nanoparticles

Volta-Duran, E, Sanchez, JM, Hector-Lopez-Laguna, Parlade, E, Sanchez-Garcia, L, Sanchez-Chardi, A, de Marco, A, Unzueta, U, Vazquez, E, Villaverde, A. The spectrum of building block conformers sustains the biophysical properties of clinically-oriented self-assembling protein nanoparticles. Science China-Materials. 2022; 65(6)DOI:10.1007/s40843-021-1914-0. PMID:. IF:8.100(Q1/3D).

01/05/2022 An In Silico Methodology That Facilitates Decision Making in the Engineering of Nanoscale Protein Materials

Parlade, E, Volta-Duran, E, Cano-Garrido, O, Sanchez, JM, Unzueta, U, Lopez-Laguna, H, Serna, N, Cano, M, Rodriguez-Mariscal, M, Vazquez, E, Villaverde, A. An In Silico Methodology That Facilitates Decision Making in the Engineering of Nanoscale Protein Materials. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022; 23(9)DOI:10.3390/ijms23094958. PMID:35563346. IF:5.600(Q1/3D).

29/04/2022 Toxicity Profiling of Bacterial Inclusion Bodies in Human Caco-2 Cells

Barguilla, I, Unzueta, U, Carratala, JV, Cano-Garrido, O, Villaverde, A, Hernandez, A, Ferrer-Miralles, N. Toxicity Profiling of Bacterial Inclusion Bodies in Human Caco-2 Cells. Frontiers in Bioengineering and Biotechnology. 2022; 10DOI:10.3389/fbioe.2022.842256. PMID:35573225. IF:5.700(Q1/3D).

01/03/2022 The Poly-Histidine Tag H6 Mediates Structural and Functional Properties of Disintegrating, Protein-Releasing Inclusion Bodies

Sanchez, JM, Carratala, JV, Serna, N, Unzueta, U, Nolan, V, Sanchez-Chardi, A, Volta-Duran, E, Lopez-Laguna, H, Ferrer-Miralles, N, Villaverde, A, Vazquez, E. The Poly-Histidine Tag H6 Mediates Structural and Functional Properties of Disintegrating, Protein-Releasing Inclusion Bodies. Pharmaceutics. 2022; 14(3)DOI:10.3390/pharmaceutics14030602. PMID:35335976. IF:5.400(Q1/2D).

01/01/2022 Insights on the emerging biotechnology of histidine-rich peptides

López-Laguna H, Voltà-Durán E, Parladé E, Villaverde A, Vázquez E, Unzueta U. Insights on the emerging biotechnology of histidine-rich peptides. BIOTECHNOLOGY ADVANCES. 2022; 54DOI:10.1016/j.biotechadv.2021.107817. PMID:34418503. IF:16.000(Q1/1D).

01/11/2021 Antibacterial Activity of T22, a Specific Peptidic Ligand of the Tumoral Marker CXCR4

Serna, N, Carratala, JV, Conchillo-Sole, O, Martinez-Torro, C, Unzueta, U, Mangues, R, Ferrer-Miralles, N, Daura, X, Vazquez, E, Villaverde, A. Antibacterial Activity of T22, a Specific Peptidic Ligand of the Tumoral Marker CXCR4. Pharmaceutics. 2021; 13(11)DOI:10.3390/pharmaceutics13111922. PMID:34834337. IF:6.525(Q1/2D).

13/09/2021 Biofabrication of functional protein nanoparticles through simple His-tag engineering

Lopez-Laguna, H, Sanchez, JM, Carratala, JV, Rojas-Pena, M, Sanchez-Garcia, L, Parlade, E, Sanchez-Chardi, A, Volta-Duran, E, Serna, N, Cano-Garrido, O, Flores, S, Ferrer-Miralles, N, Nolan, V, de Marco, A, Roher, N, Unzueta, U, Vazquez, E, Villaverde, A. Biofabrication of functional protein nanoparticles through simple His-tag engineering. ACS Sustainable Chemistry & Engineering. 2021; 9(36)DOI:10.1021/acssuschemeng.1c04256. PMID:34603855. IF:9.224(Q1/1D).

30/06/2021 Self-Assembled Nanobodies as Selectively Targeted, Nanostructured, and Multivalent Materials

Sanchez-Garcia, L, Volta-Duran, E, Parlade, E, Mazzega, E, Sanchez-Chardi, A, Serna, N, Lopez-Laguna, H, Mitstorfer, M, Unzueta, U, Vazquez, E, Villaverde, A, de Marco, A. Self-Assembled Nanobodies as Selectively Targeted, Nanostructured, and Multivalent Materials. ACS Applied Materials & Interfaces. 2021; 13(25)DOI:10.1021/acsami.1c08092. PMID:34129336. IF:10.383(Q1/2D).